SAN FRANCISCO — A study showed Bimatoprost sustained-release implant was noninferior to timolol and may potentially provide sustained IOP control for patients with open-angle glaucoma or ocular hypertension, according to a speaker here.
“The ARTEMIS implant was able to achieve its primary endpoints, and in fact it looks like it has the possibility of giving us sustained control for out to a year,” E. Randy Craven, MD, said at the American Academy of Ophthalmology annual meeting.
Craven shared the results of the ARTEMIS and APOLLO studies, both of which examined (Read more...)
Uncategorized